Gout, inflammation, and metabolic health in French Polynesia
FENUA-METABOGOUT : Genetic Landscape of Gout, Inflammation and Metabolic Diseases in French Polynesia.
This project will collect blood, urine, and genetic information to see if specific genes and molecular markers explain gout, inflammation, and metabolic problems in adults with Polynesian ancestry in French Polynesia.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2750 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Lille Catholic University Academic / other |
| Locations | 6 sites (Faa'a and 5 other locations) |
| Trial ID | NCT07343336 on ClinicalTrials.gov |
What this trial studies
This is an observational, population-based effort to map the genetic and molecular landscape of hyperuricaemia, gout, and related metabolic and inflammatory traits in French Polynesia. Investigators will enroll adults of Polynesian ancestry from general practice visits, a rheumatology clinic cohort, people with tophaceous gout, recent gout attacks, and a 2021 TOPATA follow-up group, collecting blood and urine samples and clinical/anthropometric data. Laboratory analyses will include serum urate measurements, molecular assays and genetic analyses to look for variants and biomarkers linked to MSU crystal deposition and inflammatory response. The project aims to relate molecular and genetic findings to clinical patterns and cardiometabolic comorbidities in a population with very high hyperuricaemia prevalence.
Who should consider this trial
Good fit: Adults aged 18 to 75 with self-declared Polynesian ancestry who can fast for sample collection and are affiliated to a social security scheme—including general practice visitors, patients followed at the Taaone rheumatology clinic, people with tophaceous gout, those within 48 hours of a gout attack, and prior TOPATA participants—are the intended participants.
Not a fit: People outside the 18–75 age range, those without Polynesian ancestry, those unwilling or unable to fast or provide biological samples, or those not affiliated with a social security scheme are not eligible and unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, this work could reveal genetic or molecular markers that help predict who is at highest risk for gout or guide more targeted prevention and management for Polynesian patients.
How similar studies have performed: Prior work in French Polynesia (the 2021 TOPATA cohort) and international gout genetics studies have linked hyperuricaemia to cardiometabolic traits and identified some risk loci, but the genetic drivers of MSU deposition and variable inflammatory responses remain incompletely characterized, so this project builds on existing evidence while addressing unresolved questions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: All participants: * Age between 18 and 75 years old inclusive * Signature of informed consent * Fasting for the collection of biological samples * Declared Polynesian ancestry * Affiliated to a social security scheme General population group : * Not having participated to the 2021 TOPATA study * Visiting a general practitioner (for whatever reason) Gout Group : * Managed at the rheumatology clinic of the Taaone Hospital Centre (CHT) in Papeete by Dr Baptiste Gérard. Tophaceous gout sub-group: * Present with tophaceous gout. Gout crisis subgroup: * Be within 48 hours of the onset of a gout attack * Agree to return 1 week after inclusion for the second blood and urine sample. 2021 follow-up group: * To have been included in the TOPATA study in 2021 * Have taken the genetic and biological samples that generated the genetic and serum urate data for the 2021 study * Have hyperuricaemia without signs of gout OR without hyperuricaemia or gout at the time of inclusion in TOPATA Exclusion Criteria: All participants : * Refusal or inability to understand or give consent * Physical inability to follow and respect the protocol * 1st degree relative\*, * Person under guardianship or trusteeship * Pregnant or breast-feeding woman \* If several relatives from the same household are eligible to participate, only one person may be included in the study. The choice is left to the discretion of the investigator or the first person met. However, both members of a couple (e.g. husband and wife) may participate. * General population group : * Unable to return for sampling if required. * Gout group : * Person wearing a knee prosthesis * People suffering from other inflammatory rheumatic diseases
Where this trial is running
Faa'a and 5 other locations
- Medical Office Dr Antoine Scuiller — Faa'a, French Polynesia (Recruiting)
- Medical Office Dr Cedric Gueguen — Papeete, French Polynesia (Recruiting)
- Medical Office Dr Voradeth Nouanesengsy — Papeete, French Polynesia (Recruiting)
- CH de Polynesie Française Papeete — Pirae, French Polynesia (Not_yet_recruiting)
- Medical Office Dr Nanethida Nouanesengsy — Pirae, French Polynesia (Recruiting)
- Medical Office Dr Raphael Habib — Pirae, French Polynesia (Recruiting)
Study contacts
- Principal investigator: Tristan Pascart, Professor — Ghicl
- Study coordinator: Marie De Solere
- Email: desolere.marie@ghicl.net
- Phone: +33 3 20 22 59 31
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.